Doxorubicin liposomal - Perrigo

Drug Profile

Doxorubicin liposomal - Perrigo

Alternative Names: Myocet; NSC 620212; TLC D99; TLC Dox99

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Corporation
  • Developer Sopherion Therapeutics; Zeneus Pharma
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 28 Sep 2016 Efficacy and adverse events data from a phase II trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 Cephalon completes a phase II trial in Breast cancer (Metastatic disease, First-line therapy, Combination therapy) in United Kingdom, Netherland, Austria, Belgium, France, Germany, Italy and Spain (NCT00712881)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top